1.	Phase IV Randomized Study of Doxorubicin Hydrochloride Liposome Versus Capecitabine as First-Line Chemotherapy in Women With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
2.	Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 26658, NCT00872859
3.	A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO# 08-1373, NCT00900744
4.	Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-09-14B, NCT00984269
5.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
6.	Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30008, UCLA-0311034-01, NCT00073528
7.	Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP9881B/3001, NCT00081796
8.	A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DOXIL-BCA-3001, NCT00091442
9.	ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104383, NCT00272987
10.	Luteal v. Follicular Phase Surgical Oophorectomy & Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor + Br. CA Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-0476, NCT00293540
11.	Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446E2352, NCT00320710
12.	A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR005143, NCT00338286
13.	Phase III Randomized Study of Stereotactic Radiosurgery With Versus Without Whole-Brain Radiotherapy in Patients With Cerebral Metastases Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
14.	Phase III Randomized Study of Treatment Decision Making Based on Levels of Circulating Tumor Cells in Women With Metastatic Breast Cancer Undergoing Chemotherapy Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: SWOG-S0500, S0500, CALGB-SWOG-S0500, NCT00382018
15.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
16.	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181114, NCT00428220
17.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
18.	A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR014764, NCT00580112
19.	Phase III Randomized Study of Tamoxifen Citrate or Letrozole With Versus Without Bevacizumab in Women With Hormone Receptor-Positive Stage IIIB-IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40503, CALGB 40503, NCT00601900
20.	Phase III Randomized Study of Taxane-Based Chemotherapy in Combination With Lapatinib Ditosylate Versus Trastuzumab (Herceptin®) in Women With HER2/neu-Positive Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA31, MA31, GSK-EGF108919, EUDRACT-2007-004568-27, NCT00667251
21.	Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP12-0606, TRI0-CIRG-012, TRI0-012, EUDRACT Number: 2008-001727-65, NCT00703326
22.	Phase III Randomized Study of Paclitaxel Versus Paclitaxel Albumin-Stabilized Nanoparticle Formulation Versus Ixabepilone in Combination With Bevacizumab in Patients With Locally Recurrent, Stage IIIB or IV Breast Cancer Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40502, CALGB 40502, NCT00785291
23.	Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3003, NCT00777101
24.	An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4370g, 2008-005 713-22, NCT00829166
25.	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111438, NCT00820222